The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•7 April 2026•

1 min read

Sanofi Reports Positive Phase 2 Results for Lunsekimig in Asthma and Nasal Polyps

Key Facts

1The AIRCULES phase 2b study met its primary and key secondary endpoints in moderate-to-severe asthma regardless of biomarker status.

2The DUET phase 2a study met its primary and key secondary endpoints in chronic rhinosinusitis with nasal polyps (CRSwNP).

3The exploratory VELVET phase 2b study did not meet its primary endpoint in moderate-to-severe atopic dermatitis.

Create Free Account

Version History

1 additional source confirmed this story

Sanofi announced successful results from its Phase 2 clinical trials for lunsekimig, targeting respiratory conditions. The AIRCULES Phase 2b study achieved its primary and key secondary endpoints in treating moderate-to-severe asthma. Notably, the drug showed efficacy regardless of the patient's biomarker status, significantly expanding its potential market reach. Additionally, the DUET Phase 2a study for chronic rhinosinusitis with nasal polyps (CRSwNP) also met its clinical goals. However, the exploratory VELVET Phase 2b study for atopic dermatitis failed to meet its primary endpoint. Despite this setback in dermatology, the positive respiratory data strengthens Sanofi's late-stage immunology pipeline and investor confidence.